Potential Cure for HIV Successfully Completes Approval Phase for New Drug (Pre-Ind)


Los Angeles research pioneer develops cellular immunotherapy as an alternative to antiretroviral therapy (ART)

Released: Oct 19, 2021 at 8:05 am CDT|Updated: 1 hour ago

LOS ANGELES, Oct 19, 2021 / PRNewswire / – (NASDAQ: ENOB) – A potential cure for HIV developed by groundbreaking researcher Dr. Serhat Gumrukçu, Director of the Seraph Research Institute (SRI), and his team created the Pre-Investigational New Drug (IND) for the Center for Biologics Evaluation and Research (CBER) of the US Food and Drug Administration (FDA).

“We are very encouraged by this move for the FDA to find a cure for HiV,” said Dr. Serhat Gumrukçu.

The application to the FDA was based on promising results obtained by a 54-year-old man with HIV who was unable to maintain HIV viral load suppression with antiviral therapy (ART). After the patient stopped ART and started using the new innovative SRI treatment, their blood levels with HIV infection were more effectively controlled for 365 consecutive days.

“We have been committed to supporting the HIV community for many years,” says Dr. Gumrukçu. “We’re very encouraged by this step forward for the FDA to find a cure for HIV.”

Dr. Gumrukçu is also the co-founder and inventor of Enochian BioSciences, which holds the exclusive license to the product.

“If it has been shown to be effective, [this therapy] could give hope to many who want alternatives to daily treatment, which is expensive and difficult to maintain, “says Dr. Peter Piot, former director of UNAIDS and the London School of Hygiene and Tropical Medicine in London.

About Serhat Gumrukçu, MD, PhD

Dr. Serhat Gumrukçu is Executive Director and Director of Translational Research at the Seraph Research Institute based in Los Angeles. His current research on infectious diseases focuses on the development of new approaches and mechanisms of action in antiviral therapies by co-opting virus-specific components of the viral replication machinery, on viruses such as SARS-CoV-2, HIV, HBV, influenza and Ebola. He was recently appointed to the board of the Alliance of Housing and Healing, which recently merged with the AIDS Project Los Angeles (APLA).

About the Seraph Research Institute (SRI)
Seraph Research Institute is a non-profit research institution headed by Dr. Serhat was founded and registered with the U.S. Department of Health, advancing medical science in areas of unmet need. The organization’s team of leading researchers and medical experts works to answer the fundamental questions of science – the study of disease at all levels from molecular to cellular – and physiology, from the individual to the population scale, to new approaches to be developed to help patients with incurable diseases.

About Enochian BioSciences, Inc.
Enochian BioSciences, Inc. is a biopharmaceutical company focused on developing innovative platforms for gene-modified cell and immunotherapies for the potential cure and treatment of deadly diseases. The company’s genetically modified cell and immunotherapy platforms have the potential to be applied to multiple indications, including HIV / AIDS, hepatitis B, all corona and influenza viruses, and oncology. For more information, please visit Enochianbio.com

Show original content:

SOURCE Seraph Research Institute

The above press release is courtesy of PRNewswire. The views, opinions, and statements contained in the press release are not endorsed by, nor do they necessarily reflect those of Gray Media Group, Inc.

Source link


Leave A Reply